Cited by 379TGF-β signaling in diseasesCancer Immunotherapy and BiomarkersT-cell and B-cell Immunology

The DOI matches its Crossref record; 318 of the 320 references it cites were found in a registry or an index.

Overcoming TGFβ-mediated immune evasion in cancer

Tauriello, Daniele V. F., Sancho, Elena, Batlle, Eduard·2022·Nature Reviews Cancer

Open this paper in CoChat — free account

Abstract

Transforming growth factor-β (TGFβ) signalling controls multiple cell fate decisions during development and tissue homeostasis; hence, dysregulation of this pathway can drive several diseases, including cancer. Here we discuss the influence that TGFβ exerts on the composition and behaviour of different cell populations present in the tumour immune microenvironment, and the context-dependent functions of this cytokine in suppressing or promoting cancer. During homeostasis, TGFβ controls inflammatory responses triggered by exposure to the outside milieu in barrier tissues. Lack of TGFβ exacerbates inflammation, leading to tissue damage and cellular transformation. In contrast, as tumours progress, they leverage TGFβ to drive an unrestrained wound-healing programme in cancer-associated fibroblasts, as well as to suppress the adaptive immune system and the innate immune system. In consonance with this key role in reprogramming the tumour microenvironment, emerging data demonstrate that TGFβ-inhibitory therapies can restore cancer immunity. Indeed, this approach can synergize with other immunotherapies - including immune checkpoint blockade - to unleash robust antitumour immune responses in preclinical cancer models. Despite initial challenges in clinical translation, these findings have sparked the development of multiple therapeutic strategies that inhibit the TGFβ pathway, many of which are currently in clinical evaluation.

Integrity signals

Registry

Crossref · 10.1038/s41568-021-00413-6

Cites

318 of 318 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 retracted

RETRACTED: FASN-TGF-β1-PD-L1 axis contributes to the development of resistance to NK cell cytotoxicity of cisplatin-resistant lung cancer cells
Shen, M., Tsai, Y., Zhu, R., Keng, P. C., Chen, Y., Chen, Y., & Lee, S. O. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2017.12.012 · Cited by 23
Retracted
The Immune Landscape of Cancer
Thorsson, V., Gibbs, D. L., Brown, S. D., Wolf, D., Bortone, D. S., Ou Yang, T.-H., Porta-Pardo, E., Gao, G. F., Plaisier, C. L., Eddy, J. A., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.023 · Cited by 5,870
Neutrophil recruitment and function in health and inflammation
Kolaczkowska, E., & Kubes, P. (2013) · Nature Reviews Immunology · doi:10.1038/nri3399 · Cited by 5,472
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Mariathasan, S., Turley, S. J., Nickles, D., Castiglioni, A., Yuen, K., Wang, Y., Kadel III, E. E., Koeppen, H., Astarita, J. L., Cubas, R., et al. (2018) · Nature · doi:10.1038/nature25501 · Cited by 5,400
Elements of cancer immunity and the cancer–immune set point
Chen, D. S., & Mellman, I. (2017) · Nature · doi:10.1038/nature21349 · Cited by 5,352
Conversion of Peripheral CD4+CD25− Naive T Cells to CD4+CD25+ Regulatory T Cells by TGF-β Induction of Transcription Factor Foxp3
Chen, W., Jin, W., Hardegen, N. J., Lei, K.-J., Li, L., Marinos, N. J., McGrady, G., & Wahl, S. M. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030152 · Cited by 4,678
Tumors: Wounds That Do Not Heal
Flier, J. S., Underhill, L. H., & Dvorak, H. F. (1986) · New England Journal of Medicine · doi:10.1056/nejm198612253152606 · Cited by 4,391
The biology and function of fibroblasts in cancer
Kalluri, R. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.73 · Cited by 4,366
Myofibroblasts and mechano-regulation of connective tissue remodelling
Tomasek, J. J., Gabbiani, G., Hinz, B., Chaponnier, C., & Brown, R. A. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm809 · Cited by 4,290
Innate and adaptive immune cells in the tumor microenvironment
Gajewski, T. F., Schreiber, H., & Fu, Y.-X. (2013) · Nature Immunology · doi:10.1038/ni.2703 · Cited by 4,148

Show all 320 references

Sorted by citations

Mitochondrial dynamics in health and disease: mechanisms and potential targets
Chen, W., Zhao, H., & Li, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01547-9 · Cited by 1,306
The cancer-immunity cycle: Indication, genotype, and immunotype
Mellman, I., Chen, D. S., Powles, T. B., & Turley, S. J. (2023) · Immunity · doi:10.1016/j.immuni.2023.09.011 · Cited by 1,018
TGF-β signaling in health and disease
Massagué, J., & Sheppard, D. (2023) · Cell · doi:10.1016/j.cell.2023.07.036 · Cited by 890
The hallmarks of cancer immune evasion
Galassi, C., Chan, T. A.-T., Vitale, I., & Galluzzi, L. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.09.010 · Cited by 630
Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches
Tufail, M., Jiang, C., & Li, N. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02280-1 · Cited by 454
Cancer-Associated Fibroblasts in Inflammation and Antitumor Immunity
Kennel, K. B., Bozlar, M., Valk, A. F. D., & Greten, F. R. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1031 · Cited by 297
Mechanisms driving the immunoregulatory function of cancer cells
van Weverwijk, A., & de Visser, K. E. (2023) · Nature reviews. Cancer · doi:10.1038/s41568-022-00544-4 · Cited by 288
Roles of cancer-associated fibroblasts (CAFs) in anti- PD-1/PD-L1 immunotherapy for solid cancers
Pei, L., Liu, Y., Liu, L., Gao, S., Gao, X., Feng, Y., Sun, Z., Zhang, Y., & Wang, C. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01731-z · Cited by 270
Mechanisms of metastatic colorectal cancer
Cañellas-Socias, A., Sancho, E., & Batlle, E. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-024-00934-z · Cited by 284
Self-citation
Advances in molecular pathology and therapy of non-small cell lung cancer
Huang, Q., Li, Y., Huang, Y., Wu, J., Bao, W., Xue, C., Li, X., Dong, S., Dong, Z., & Hu, S. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02243-6 · Cited by 197
NK cells and solid tumors: therapeutic potential and persisting obstacles
Tong, L., Jiménez‐Cortegana, C., Tay, A. H. M., Wickström, S. L., Galluzzi, L., & Lundqvist, A. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01672-z · Cited by 197
WNT signaling and cancer stemness
Katoh, M., & Katoh, M. (2022) · Essays in Biochemistry · doi:10.1042/ebc20220016 · Cited by 188
TGF-beta signal transduction: biology, function and therapy for diseases
Tie, Y., Tang, F., Peng, D., Zhang, Y., & Shi, H. (2022) · Molecular Biomedicine · doi:10.1186/s43556-022-00109-9 · Cited by 186
TGF-β, EMT, and resistance to anti-cancer treatment
Wang, X., Eichhorn, P. J. A., & Thiery, J. P. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.10.004 · Cited by 187
ATP and Adenosine Metabolism in Cancer: Exploitation for Therapeutic Gain
Yegutkin, G. G., & Boison, D. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.121.000528 · Cited by 179
Tumor battlefield within inflamed, excluded or desert immune phenotypes: the mechanisms and strategies
Zheng, S., Wang, W., Shen, L., Yao, Y., Xia, W., & Ni, C. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00543-1 · Cited by 200
Localization, tissue biology and T cell state — implications for cancer immunotherapy
Schenkel, J. M., & Pauken, K. E. (2023) · Nature reviews. Immunology · doi:10.1038/s41577-023-00884-8 · Cited by 144
Extracellular matrix dynamics in tumor immunoregulation: from tumor microenvironment to immunotherapy
Hu, Q., Zhu, Y., Mei, J., Liu, Y. L., & Zhou, G. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01717-y · Cited by 157
Toll-like receptor 9 agonists and combination therapies: strategies to modulate the tumour immune microenvironment for systemic anti-tumour immunity
Dongye, Z., Li, J., & Wu, Y. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01876-6 · Cited by 138
The chemokine monocyte chemoattractant protein-1/CCL2 is a promoter of breast cancer metastasis
Yoshimura, T., Li, C., Wang, Y., & Matsukawa, A. (2023) · Cellular and Molecular Immunology · doi:10.1038/s41423-023-01013-0 · Cited by 128
Macrophage polarization in cancer and beyond: from inflammatory signaling pathways to potential therapeutic strategies
Bai, X., Guo, Y.-R., Zhao, Z., Li, X., Dai, D.-Q., Zhang, J., Li, Y.-S., & Zhang, C. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217772 · Cited by 140
Application of radiomics-based multiomics combinations in the tumor microenvironment and cancer prognosis
Kang, W., Qiu, X., Luo, Y., Luo, J., Liu, Y., Xi, J., Li, X., & Yang, Z. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04437-4 · Cited by 127
Targeting inflammation as cancer therapy
Wang, M., Chen, S., He, X., Yuan, Y., & Wei, X. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01528-7 · Cited by 126
Neutrophil Extracellular Traps, Angiogenesis and Cancer
Poto, R., Cristinziano, L., Modestino, L., de Paulis, A., Marone, G., Loffredo, S., Galdiero, M. R., & Varricchi, G. (2022) · Biomedicines · doi:10.3390/biomedicines10020431 · Cited by 120
Hepatocellular carcinoma: signaling pathways, targeted therapy, and immunotherapy
Luo, X., He, X., Zhang, X., Zhao, X., Zhang, Y., Shi, Y., & Hua, S. (2024) · MedComm · doi:10.1002/mco2.474 · Cited by 115
Recent Developments in Layer‐by‐Layer Assembly for Drug Delivery and Tissue Engineering Applications
Borges, J., Zeng, J., Liu, X. Q., Chang, H., Monge, C., Garot, C., Ren, K., Machillot, P., Vrana, N. E., Lavall�e, P., et al. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202302713 · Cited by 105
Convergent inducers and effectors of T cell paralysis in the tumour microenvironment
Hanahan, D., Michielin, O. A., & Pittet, M. J. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00761-z · Cited by 106
TGF-β: A novel predictor and target for anti-PD-1/PD-L1 therapy
Yi, M., Li, T., Niu, M., Wu, Y., Zhao, Z., & Wu, K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1061394 · Cited by 95
TME-Related Biomimetic Strategies Against Cancer
Peng, C., Xu, Y., Wu, J., Wu, D., Zhou, L., & Xia, X. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s441135 · Cited by 93
Myeloid-Derived Suppressor Cells and Radiotherapy
Jiménez‐Cortegana, C., Galassi, C., Klapp, V., Gabrilovich, D. I., & Galluzzi, L. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-1105 · Cited by 88
The difficulty in translating the preclinical success of combined TGFβ and immune checkpoint inhibition to clinical trial
Metropulos, A. E., Munshi, H. G., & Principe, D. R. (2022) · eBioMedicine · doi:10.1016/j.ebiom.2022.104380 · Cited by 81
Super-enhancer hijacking LINC01977 promotes malignancy of early-stage lung adenocarcinoma addicted to the canonical TGF-β/SMAD3 pathway
Zhang, T., Xia, W., Song, X., Mao, Q., Huang, X., Chen, B., Liang, Y., Wang, H., Chen, Y., Yu, X., et al. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01331-2 · Cited by 85
Interventional hydrogel microsphere vaccine as an immune amplifier for activated antitumour immunity after ablation therapy
Liu, X., Zhuang, Y., Huang, W., Wu, Z., Chen, Y., Shan, Q., Zhang, Y., Wu, Z., Ding, X., Qiu, Z., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39759-w · Cited by 91
Oxidative Stress and Inflammation: Drivers of Tumorigenesis and Therapeutic Opportunities
Wang, M., Xiao, Y., Miao, J., Zhang, X., Liu, M., Zhu, L., Liu, H., Shen, X., Wang, J., Xie, B., et al. (2025) · Antioxidants · doi:10.3390/antiox14060735 · Cited by 101
Smart Lipid Nanoparticle that Remodels Tumor Microenvironment for Activatable H 2 S Gas and Photodynamic Immunotherapy
Wu, L., Liu, Y., Zeng, W., Ishigaki, Y., Zhou, S., Wang, X., Sun, Y., Zhang, Y., Jiang, X., Suzuki, T., et al. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.3c11328 · Cited by 84
TGF-β Signaling in Metastatic Colorectal Cancer (mCRC): From Underlying Mechanism to Potential Applications in Clinical Development
Li, X.-S., Wu, Y., & Tian, T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232214436 · Cited by 83
Nanoparticle-mediated TRPV1 channel blockade amplifies cancer thermo-immunotherapy via heat shock factor 1 modulation
Li, T., Jiang, S., Zhang, Y., Luo, J., Li, M., Ke, H., Deng, Y., Yang, T., Sun, X., & Chen, H. (2023) · Nature Communications · doi:10.1038/s41467-023-38128-x · Cited by 82
The strategies to cure cancer patients by eradicating cancer stem-like cells
Mai, Y., Su, J., Yang, C., Xia, C., & Fu, L. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01867-y · Cited by 78
Mapping Phenotypic Plasticity upon the Cancer Cell State Landscape Using Manifold Learning
Burkhardt, D. B., Juan, B. P. S., Lock, J. G., Krishnaswamy, S., & Chaffer, C. L. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0282 · Cited by 74
The Cytokine Network in Colorectal Cancer: Implications for New Treatment Strategies
Braumüller, H., Mauerer, B., Andris, J., Berlin, C., Wieder, T., & Kesselring, R. (2022) · Cells · doi:10.3390/cells12010138 · Cited by 81
UPP1 promotes lung adenocarcinoma progression through the induction of an immunosuppressive microenvironment
Li, Y., Jiang, M., Aye, L., Luo, L., Zhang, Y., Xu, F., Wei, Y., Peng, D., He, X., Gu, J., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45340-w · Cited by 71
Interleukin-6 (IL-6)-associated tumor microenvironment remodelling and cancer immunotherapy
Wu, S., Cao, Z., Lu, R., Zhang, Z., Sethi, G., & You, Y. (2025) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2025.01.001 · Cited by 70
Immune checkpoint blockade resistance in lung cancer: emerging mechanisms and therapeutic opportunities
Konen, J. M., Wu, H., & Gibbons, D. L. (2024) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2024.04.006 · Cited by 73
Cancer stem cell in prostate cancer progression, metastasis and therapy resistance
Verma, P., Shukla, N., Kumari, S., Ansari, M. S., Gautam, N. K., & Patel, G. K. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.188887 · Cited by 67
Small-molecule agents for cancer immunotherapy
Wang, F., Fu, K., Wang, Y., Pan, C., Wang, X., Liu, Z., Yang, C., Zheng, Y. Y., Li, X., Lu, Y., et al. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.12.010 · Cited by 71
Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities
Yin, N., Li, X., Zhang, X., Xue, S., Cao, Y., Niedermann, G., Lu, Y., & Xue, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01826-z · Cited by 74
Nanodrug Inducing Autophagy Inhibition and Mitochondria Dysfunction for Potentiating Tumor Photo‐Immunotherapy
Xiao, H. P., Li, X., Li, B., Yang, S., Qin, J., Han, S., Ren, J., & Shuai, X. (2023) · Small · doi:10.1002/smll.202300280 · Cited by 63
The enhanced antitumor activity of bispecific antibody targeting PD-1/PD-L1 signaling
Li, T., Niu, M., Zhou, J., Wu, K., & Yi, M. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01562-5 · Cited by 64
Context-dependent TGFβ family signalling in cell fate regulation
Richardson, L., Wilcockson, S. G., Guglielmi, L., & Hill, C. S. (2023) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-023-00638-3 · Cited by 63
TGF-β builds a dual immune barrier in colorectal cancer by impairing T cell recruitment and instructing immunosuppressive SPP1+ macrophages
Henriques, A. R., Salvany, M., Nieto, P., Palomo‐Ponce, S., Sevillano, M., Hernando‐Momblona, X., Guerra, E. M., Llanses, M., Haak, E., Nieto, J. C., et al. (2025) · Nature Genetics · doi:10.1038/s41588-025-02380-2 · Cited by 63
Self-citation
The Landscape of Immunotherapy Resistance in NSCLC
Frisone, D., Friedlaender, A., Addeo, A., & Tsantoulis, P. K. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.817548 · Cited by 60
TGF-β signaling pathway: Therapeutic targeting and potential for anti-cancer immunity
Ali, S., Rehman, M. U., Yatoo, A. M., Arafah, A. M., Khan, A., Rashid, S., Majid, S., Ali, A., & Ali, M. N. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175678 · Cited by 60
TGF-β Modulated Pathways in Colorectal Cancer: New Potential Therapeutic Opportunities
Fasano, M., Pirozzi, M., Miceli, C. C., Cocule, M., Caraglia, M., Boccellino, M., Vitale, P., Falco, V. D., Farese, S., Zotta, A., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137400 · Cited by 65
Recent Advances in Immune-Based Therapies for Acute Myeloid Leukemia
Restelli, C., Ruella, M., Paruzzo, L., Tarella, C., Pelicci, P. G., & Colombo, E. (2024) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-23-0202 · Cited by 58
Enhancing human NK cell antitumor function by knocking out SMAD4 to counteract TGFβ and activin A suppression
Rea, A., Santana-Hernández, S., Villanueva, J., Sanvicente-García, M., Cabo, M., Suárez-Olmos, J., Quimis, F. G., Qin, M., Llorens, E., Blasco-Benito, S., et al. (2025) · Nature Immunology · doi:10.1038/s41590-025-02103-z · Cited by 57
Integrated Machine Learning and Single-Sample Gene Set Enrichment Analysis Identifies a TGF-Beta Signaling Pathway Derived Score in Headneck Squamous Cell Carcinoma
Wu, S., Lv, X., Li, Y., Gao, X., Ma, Z., Fu, X., & Li, Y. (2022) · Journal of Oncology · doi:10.1155/2022/3140263 · Cited by 52
Rebalancing TGFβ1/BMP signals in exhausted T cells unlocks responsiveness to immune checkpoint blockade therapy
Saadey, A. A., Yousif, A., Osborne, N., Shahinfar, R., Chen, Y., Laster, B., Rajeev, M., Bauman, P., Webb, A., & Ghoneim, H. E. (2022) · Nature Immunology · doi:10.1038/s41590-022-01384-y · Cited by 47
The Love-Hate Relationship Between TGF-β Signaling and the Immune System During Development and Tumorigenesis
Chen, B., Mu, C., Zhang, Z., He, X., & Liu, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.891268 · Cited by 48
Bispecific antibody targeting TGF-β and PD-L1 for synergistic cancer immunotherapy
Li, T., Wang, X., Niu, M., Wang, M., Zhou, J., Wu, K., & Yi, M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1196970 · Cited by 52
Blocking tumor-platelet crosstalk to prevent tumor metastasis via reprograming glycolysis using biomimetic membrane-hybridized liposomes
Zhu, J., Wang, R., Yang, C., Shao, X., Zhang, Y., Hou, J., Gao, Y., Ou, A., Chen, M., & Huang, Y. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.12.052 · Cited by 45
Efficacy and safety of bispecific antibodies vs. immune checkpoint blockade combination therapy in cancer: a real-world comparison
Cheng, L., Chen, L., Shi, Y., Gu, W., Ding, W., Zheng, X. W., Liu, Y., Jiang, J., & Zheng, Z. (2024) · Molecular Cancer · doi:10.1186/s12943-024-01956-6 · Cited by 49
Clinical Challenges of Consensus Molecular Subtype CMS4 Colon Cancer in the Era of Precision Medicine
Mouillet-Richard, S., Cazelles, A., Sroussi, M., Gallois, C., Taieb, J., & Laurent-Puig, P. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-3964 · Cited by 43
Flash Radiotherapy: Innovative Cancer Treatment
Chow, J. C. L., & Ruda, H. E. (2023) · Encyclopedia · doi:10.3390/encyclopedia3030058 · Cited by 43
Spatial resolution of cellular senescence dynamics in human colorectal liver metastasis
Garbarino, O., Lambroia, L., Basso, G., Marrella, V., Franceschini, B., Soldani, C., Pasqualini, F., Giuliano, D., Costa, G., Peano, C., et al. (2023) · Aging Cell · doi:10.1111/acel.13853 · Cited by 43
“Then, to define the impact of TGFβ on SMCCs, we focused on its known anti- proliferative properties.”
BackgroundInfluential
Advances in Targeted and Chemotherapeutic Strategies for Colorectal Cancer: Current Insights and Future Directions
Shaham, S. H., Vij, P., & Tripathi, M. K. (2025) · Biomedicines · doi:10.3390/biomedicines13030642 · Cited by 47
The immunosuppressive landscape in tumor microenvironment
Liu, W., Zhou, H., Lai, W., Hu, C., Xu, R., Gu, P., Luo, M., Zhang, R., & Li, G. (2024) · Immunologic Research · doi:10.1007/s12026-024-09483-8 · Cited by 44
Mutant RAS and the tumor microenvironment as dual therapeutic targets for advanced colorectal cancer
Janssen, J. B. E., Medema, J. P., Gootjes, E. C., Tauriello, D. V. F., & Verheul, H. M. W. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102433 · Cited by 42
Self-citation
Anti-TGF-β/PD-L1 bispecific antibody synergizes with radiotherapy to enhance antitumor immunity and mitigate radiation-induced pulmonary fibrosis
Wu, Y., Yan, Y., Guo, Y., Niu, M., Zhou, B., Zhang, J., Zhou, P., Chu, Q., Mei, Q., Yi, M., et al. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01678-2 · Cited by 43
Multi-armored allogeneic MUC1 CAR T cells enhance efficacy and safety in triple-negative breast cancer
Erler, P., Kurćon, T., Cho, H., Skinner, J. N., Dixon, C., Grudman, S., Rozlan, S., Dessez, E., Mumford, B., Jo, S., et al. (2024) · Science Advances · doi:10.1126/sciadv.adn9857 · Cited by 41
Single-cell and spatial transcriptomics integration: new frontiers in tumor microenvironment and cellular communication
Shi, W., Zhang, Z., Xu, X., Tian, Y., Feng, L., Huang, X., Du, Y., & Li, Z. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1649468 · Cited by 45
Perfluorotributylamine-Loaded Albumin Nanoparticles Downregulate Platelet-Derived TGFβ to Inhibit Tumor Metastasis
Luo, L., Zhang, B., Tao, F., Chen, Z., Ye, Q., Zhao, X., & Wu, J. (2023) · ACS Nano · doi:10.1021/acsnano.3c00295 · Cited by 38
Growth factors in the treatment of Achilles tendon injury
Lin, M., Li, W., Ni, X., Yu, S., Li, H., Chen, X., Lu, Y., Jiang, M., & Wang, C. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1250533 · Cited by 37
Radiation-induced lung injury: from mechanism to prognosis and drug therapy
Wang, S., Xu, D., Xiao, L., Liu, B., & Yuan, X. (2025) · Radiation Oncology · doi:10.1186/s13014-025-02617-8 · Cited by 43
Mutual regulation of TGFβ-induced oncogenic EMT, cell cycle progression and the DDR
Schuhwerk, H., & Brabletz, T. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.11.009 · Cited by 35
Preclinical and clinical studies of bintrafusp alfa, a novel bifunctional anti-PD-L1/TGFβRII agent: Current status
Gameiro, S. R., Strauss, J., Gulley, J. L., & Schlom, J. (2022) · Experimental Biology and Medicine · doi:10.1177/15353702221089910 · Cited by 35
SOX12 Facilitates Hepatocellular Carcinoma Progression and Metastasis through Promoting Regulatory T‐Cells Infiltration and Immunosuppression
Luo, X., Huang, W., Li, S., Sun, M., Hu, D. X., Jiang, J., Zhang, Z., Wang, Y., Wang, Y., Zhang, J., et al. (2024) · Advanced Science · doi:10.1002/advs.202310304 · Cited by 33
Pharmacological suppression of the OTUD4/CD73 proteolytic axis revives antitumor immunity against immune-suppressive breast cancers
Zhu, Y., Banerjee, A., Xie, P., Ivanov, A. A., Uddin, A., Jiao, Q., Chi, J. J., Zeng, L., Lee, J. Y., Xue, Y., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci176390 · Cited by 37
MDSC: a new potential breakthrough in CAR-T therapy for solid tumors
Abdalsalam, N. M. F., Ibrahim, A., Saliu, M. A., Liu, T., Wan, X., & Yan, D. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01995-y · Cited by 35
The radiobiology of TGFβ
Barcellos‐Hoff, M. H. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.02.001 · Cited by 36
Up-regulated PLA2G10 in cancer impairs T cell infiltration to dampen immunity
Zhang, T., Yu, W., Cheng, X., Yeung, J. T., Ahumada, V., Norris, P. C., Pearson, M. J., Yang, X., van Deursen, W. H., Halcovich, C., et al. (2024) · Science Immunology · doi:10.1126/sciimmunol.adh2334 · Cited by 32
Radiotherapy enhances the anti-tumor effect of CAR-NK cells for hepatocellular carcinoma
Lin, X., Liu, Z., Dong, X., Wang, K., Sun, Y., Zhang, H., Wang, F., Chen, Y., Jing, L., Guo, Y., et al. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05724-4 · Cited by 32
Claudin 1, 4, 6 and 18 isoform 2 as targets for the treatment of cancer (Review)
Katoh, M., & Katoh, M. (2024) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2024.5424 · Cited by 34
Immunological control of ovarian carcinoma by chemotherapy and targeted anticancer agents
Fucikova, J. P., Palová-Jelínková, L., Klapp, V., Holíček, P., Láníčková, T., Kašíková, L., Drozenová, J., Cibula, D., Álvarez-Abril, B., García-Martínez, E., et al. (2022) · Trends in cancer · doi:10.1016/j.trecan.2022.01.010 · Cited by 32
Hypoxic tumor microenvironment: Destroyer of natural killer cell function
Zhang, Y., Guo, F., & Wang, Y. (2024) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2024.02.04 · Cited by 32
Cancer-Homing CAR-T Cells and Endogenous Immune Population Dynamics
Guerra, E., Pietro, R. D., Basile, M., Trerotola, M., & Alberti, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010405 · Cited by 30
TIM-3 Expression and M2 Polarization of Macrophages in the TGFβ-Activated Tumor Microenvironment in Colorectal Cancer
Katagata, M., Okayama, H., Nakajima, S., Saito, K., Sato, T., Sakuma, M., Fukai, S., Endo, E., Sakamoto, W., Saito, M., et al. (2023) · Cancers · doi:10.3390/cancers15204943 · Cited by 31
ZEB1-mediated fibroblast polarization controls inflammation and sensitivity to immunotherapy in colorectal cancer
Menche, C., Schuhwerk, H., Armstark, I., Gupta, P., Fuchs, K., van Roey, R., Mosa, M. H., Hartebrodt, A., Hajjaj, Y., Ezquerra, A. C., et al. (2024) · EMBO Reports · doi:10.1038/s44319-024-00186-7 · Cited by 31
Coengineering specificity, safety, and function into T cells for cancer immunotherapy
Attianese, G. M. P. G., Ash, S., & Irving, M. B. (2023) · Immunological Reviews · doi:10.1111/imr.13252 · Cited by 29
Nanomaterial-assisted CRISPR gene-engineering – A hallmark for triple-negative breast cancer therapeutics advancement
Farheen, J., Hosmane, N. S., Zhao, R., Zhao, Q. D., Iqbal, M. Z., & Kong, X. (2022) · Materials Today Bio · doi:10.1016/j.mtbio.2022.100450 · Cited by 29
γδ T Cell‐mediated Tumor Immunity is Tightly Regulated by STING and TGF‐β Signaling Pathways
Luo, J., Wang, S., Yang, Q., Fu, Q., Zhu, C., Li, T., Yang, S., Zhao, Y., Guo, R., Ben, X., et al. (2024) · Advanced Science · doi:10.1002/advs.202404432 · Cited by 26
A review of obstructive sleep apnea and lung cancer: epidemiology, pathogenesis, and therapeutic options
Fang, Y., Hu, Y., Xu, F., & Feng, X. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1374236 · Cited by 29
Convergent evolution of a parasite-encoded complement control protein-scaffold to mimic binding of mammalian TGF-β to its receptors, TβRI and TβRII
Mukundan, A., Byeon, C., Hinck, C. S., Cunningham, K. T., Campion, T., Smyth, D. J., Maizels, R. M., & Hinck, A. P. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.101994 · Cited by 22
SMAD4, activated by the TCR-triggered MEK/ERK signaling pathway, critically regulates CD8 + T cell cytotoxic function
Liu, X., Hao, J., Wei, P., Zhao, X., Lan, Q., Ni, L., Chen, Y., Bai, X., Ni, L., & Dong, C. (2022) · Science Advances · doi:10.1126/sciadv.abo4577 · Cited by 26
Charting the Course: Sequencing Immunotherapy for Multiple Myeloma
Mohan, M., Oekelen, O. V., Akhtar, O. S., Cohen, A. D., & Parekh, S. S. (2024) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_432204 · Cited by 27
Targeting IL-33 reprograms the tumor microenvironment and potentiates antitumor response to anti-PD-L1 immunotherapy
Nan, Y., Bai, Y., Hu, X., Zhou, K., Wu, T., Zhu, A., Li, M., Dou, Z., Cao, Z., Zhang, X., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009236 · Cited by 26
Increased peritoneal TGF-β1 is associated with ascites-induced NK-cell dysfunction and reduced survival in high-grade epithelial ovarian cancer
Maas, R. J. A., Evert, J. S. H., Hagemans, I. M., Brummelman, J., van Ens, D., de Jonge, P. K. J. D., Hooijmaijers, L., Mahajan, S., van der Waart, A. B., Hermans, C. K. J. C., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1448041 · Cited by 28
Self-citation
Natural photothermal-responsive MXene-based antimicrobial nanomaterials Ti3C2/Au NPs for the treatment of deep Staphylococcus aureus-Infected wound
Chen, X., Wang, J., Endo, Y., Liu, G., Wang, N., & Shao, Z. (2023) · Materials & Design · doi:10.1016/j.matdes.2023.112138 · Cited by 24
Understanding and Overcoming Immunosuppression Shaped by Cancer Stem Cells
Li, L., & Jensen, R. A. (2023) · Cancer Research · doi:10.1158/0008-5472.can-23-0230 · Cited by 24
Potentiating anti-tumor immunity by re-engaging immune synapse molecules
Zhou, X., Xu, T., Li, C., He, Y., Hu, Y., Gong, H., Li, J., Jiang, H., Wen, L., Fu, Y., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.101975 · Cited by 23
Triple targeting of STING, TGF-β, and PD-L1 boosts CXCL16–CXCR6 signaling for potent antitumor response
Yi, M., Li, T., Gu, Y., Niu, M., Xue, D., Hu, S., Wu, Y., Zhao, B., Zhang, D., Ma, Y., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-69456-3 · Cited by 26

Authors: Tauriello, D. V. F., Sancho, E., & Batlle, E.
Affiliations: Radboud University Medical Center (NL)
Institute for Research in Biomedicine (ES)
Institució Catalana de Recerca i Estudis Avançats (ES)
Corresponding author: Tauriello, Daniele V. F.
Batlle, Eduard
ORCID: Tauriello, Daniele V. F.
Sancho, Elena
Batlle, Eduard
Venue: Nature Reviews Cancer
Publisher: Springer Science and Business Media LLC
Published: 2021-10-20
Volume: 22
Issue: 1
Pages: 25-44
ISSN: 1474-175X (ISSN-L)
1474-1768
DOI: 10.1038/s41568-021-00413-6
OpenAlex: W3206061095
Cited by: 377
References: 320
Citations by year: 2026: 65 · 2025: 101 · 2024: 93 · 2023: 61 · 2022: 55 · 2021: 2
FWCI: 5.58
Type: journal article
Language: en
Open access: closed
Licence: www.springernature.com/gp/researchers/text-and-data-mining (tdm)
www.springernature.com/gp/researchers/text-and-data-mining (vor)
Locations: Nature reviews. Cancer (publishedVersion)
PubMed (publishedVersion)
Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, public-domain)
Radboud Repository (Radboud University) (submittedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords: TGF-beta signaling, tumor immune microenvironment, immune evasion, cancer-associated fibroblasts, innate immune suppression, TGF-beta inhibition, cancer immunotherapy, immune checkpoint blockade
MeSH terms: Humans, Immunotherapy, Neoplasms, Transforming Growth Factor beta, Immune Evasion, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Overcoming TGFβ-mediated immune evasion in cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks